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Background:The purpose of these clinical guidelines, commissioned by the
Italian Society of Periodontology and compiled with the tools and instructions
of the Appraisal of Guidelines for Research and Evaluation (AGREE) collabo-
ration, was to determine, in terms of efficacy, complications, and patient opin-
ions, the most appropriate surgical techniques for periodontal patients with
infrabony defects ‡3 mm.
Methods: Results published in the literature concerning open flap debride-
ment (OFD), guided tissue regeneration (GTR) using a bioabsorbable or non-
resorbablemembrane, regenerationofperiodontal tissuesusing enamelmatrix
derivative (EMD), and bone or bone substitute grafts were searched (electron-
ically and manually) and compared. The following variables were analyzed:
number of teeth lost, variation in clinical attachment level (CALgain), variation
in probing depth (PD reduction), variation in gingival recession, variation in
bony defect depth (bone gain), complications, and the functional and esthetic
satisfaction of the patients. Literature searches were performed selecting ran-
domized clinical trials (RCTs) and systematic reviews (SRs) of RCTs published
through December 31, 2006 with ‡1 year of follow-up. The full text of the se-
lected SRs and RCTs were analyzed using checklists for qualitative evaluation
according to the Scottish Intercollegiate Guidelines Network (SIGN) method.
Results: For the drafting of these guidelines, it was decided to accept the re-
sults of two SRs that compared OFD versus GTR, OFD versus EMD, and GTR
versusEMD.With regard to efficacy,GTRandEMDcanyield better results than
OFD in terms of CAL gain (1.22 mm [P value <0.0001] and 1.20 mm [P value
<0.0001], respectively), reduction of PD (1.21 mm [P = 0.0004] and 0.77 mm
[P = 0.0001], respectively), and bone gain (1.39 and 1.08 mm, respectively)
after ‡1 year of follow-up. The available data are insufficient for an evaluation
of bone or bone substitute grafts. The data in the literature are also insufficient
for answering questions about complications and patient opinions.
Conclusions:Theevidence reported in the literature indicates that it is advis-
able to treat infrabony defects ‡3mmbyOFD, GTR, and EMD. Further studies
on these topics shouldbeencouraged.There is aneed forwell-conductedRCTs
that report data on complications and patient opinions. J Periodontol 2008;
79:2219-2232.
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Periodontitis is an in-fectious disease ofthe gums and tissue
surrounding the teeth
that can occur in various
forms. According to re-
cent studies, advanced
forms of periodontitis af-
fect 5% to 15% of the
population aged 35 to
44 years, whereas ag-
gressive forms strike
;2% of all adolescents.1
In the United States, 50%
of the population has
bleeding gums, and 35%
has periodontitis.2,3
Periodontitis is an op-
portunistic infectious dis-
ease associated with
somebacterialpopulations
present in dental plaque
that are capable of trigger-
ing an inflammatory re-
sponse in the periodontal
tissues of susceptible
subjects.4 Under normal
conditions, there is an equi-
librium between host and
bacteria; however, some
conditions can alter this
balance in favor of bacte-
rial aggression.4 Some risk
factors(smoking,diabetes,
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interleukin-1 genetic polymorphism, and familiarity)
can aggravate the inflammatory process.5 Progres-
sion of the disease can lead to the destruction of the
periodontal supporting tissues,with loss of connective
tissueattachmentandalveolarbone,manifesting itself
clinically through the development of recessions and/
or pockets.6
As the disease progresses, symptoms may include
bleedinggums,periodontal abscesses, increased tooth
mobility due to the loss of bone support, tooth migra-
tion, exposure of the root surface, and tooth loss.7,8
Treatment of periodontitis calls for, first of all, con-
trolling the cause (causal therapy), i.e., reducing the
bacterial load on the tooth by mechanical treatment
above and below the gum (scaling and root planing),
pharmacologic treatment (local and/or general) when
indicated, and instructing and motivating the patient
in home oral hygiene techniques.8,9
After causal treatment, the periodontal patient usu-
ally presents a reduction in dental plaque and in
bleeding on probing (the clinical symptom of inflam-
mation of periodontal tissues) and a decrease in prob-
ing depth (PD).
The pockets remaining after causal treatment are
ecologic niches that facilitate the formation of subgin-
gival biofilm. They can lead to progression of the dis-
ease despite professional maintenance therapy and
good patient compliance with oral hygiene prac-
tices.10 In these cases, periodontal therapy calls for
additional surgical treatment to reduce or eliminate
the pockets and the associated bony defects to make
it easier and simpler for the patient to remove plaque
on his or her own.
Various surgical approaches have been proposed
for the treatment of residual defects, with different indi-
cations for different defects. In particular, for infrabony
or angular defects (the result of vertical destruction of
the bone adjacent to the tooth caused by the disease)
‡3 mm, the current literature offers five techniques:
openinga surgical flap to remove thegranulation tissue
adjacent to and inside the bony defect as well as any
hard (tartar) and soft (biofilm) residue that may be
on the root surface (open flap debridement [OFD]);11
guided tissue regeneration (GTR) using a bioabsorb-
able or non-resorbable membrane;12 tissue regenera-
tion using enamel matrix derivatives (amelogenin
[EMD]);13 filling the defectwith boneor bone substitute
grafts;14 and a combined approach (membrane, ame-
logenin, and bone or bone substitute grafts).8
Good patient compliance, in terms of oral hygiene at
home,andperiodicfollow-upandmaintenancevisitsare
fundamental for thesuccessof thesetreatments:without
them theperiodontal tissues canbe soon recolonizedby
the bacterial populations that caused the disease.15
These clinical guidelines, commissioned by the Ital-
ian Society of Periodontology (SIdP), Florence, Italy,
compliedwiththetoolsandinstructionsoftheAppraisal
of Guidelines for Research and Evaluation (AGREE)
Collaboration.16 The guidelines were developed by
multidisciplinary development groups and based on a
systematic review of the evidence of best practice fol-
lowing a standard methodology designed to balance
scientific rigorwithanopenandconsultativeapproach.
The aim of these clinical guidelines was to determine
which surgical techniques are most appropriate for
periodontal patients with infrabony defects ‡3 mm.
The key clinical issues included:
Efficacy: Which surgical technique is the most ap-
propriate among OFD, GTR, EMD, and bone or bone
substitute grafts, and what are the expected clinical
outcomes in periodontal patients who have already
successfully undergone causal therapy?
Complications: What are the potential adverse re-
actions following OFD, GTR, EMD, and bone or bone
substitute graft procedures?
Patient opinions: What is the level of patient satis-
faction from the functional and esthetic standpoints
following OFD, GTR, EMD, and bone or bone substi-
tute grafts?
MATERIALS AND METHODS
Development of the Guidelines
Five authors (UP, MN, RR, FC, and GP) were chosen
by SIdP and the Committee on Intersociety Coordi-
nation of the Italian Dental Societies, Urbino, Italy,
to develop the clinical guidelines. At the same time,
internal (ME and GC) and external (PC) reviewers
were identified.
When the first draft of the manuscript was com-
pleted, it underwent the two internal reviewers’ judg-
ment to reach an agreement on the guidelines. If
reaching unanimity was difficult, final agreement was
obtained by a discussion involving all members of the
research team. Subsequently, the guidelines were sent
to the external reviewer for the definitive agreement.
Who Benefits From the Guidelines
General dentists, dental hygienists, general medical
practitioners, dental specialists (periodontists), pa-
tients, and members of commercial organizations will
benefit from the guidelines.
Updates
The guidelineswill be updated at least every 3 years or
when requested by SIdP. The guidelines will also be
tested in some hospital and/or university settings
and in some private practices selected by SIdP to ver-
ify user satisfaction (health professionals and pa-
tients). The data collected will be published on the
society’s Web site to update the guidelines. These
guidelineswill be published on theWeb site of the SIdP
as part of the services offered to members, patients,
and visitors in general.
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Inclusion Criteria for Drafting the Guidelines
The objectives and inclusion criteria were organized
using PICO,17 a worksheet assessment that uses four
categories (Patient characteristics, Interventions to
investigate, Comparison of interventions, and consid-
eredOutcomes variables) for breaking downand con-
verting the issues to investigate and the information
sought into specific, precise questions. According to
PICO, a well-structured research strategy calls for at
least four questions that define the characteristics of
the patient (patient or population [P]), the treatments
to investigate (intervention [I]), the comparisons
among the identified treatments (comparison [C]),
and the outcome variables considered important for
the evaluation of the results (outcomes [O]).17
Patient identification. Patient identification included
patients presenting angular bony defects‡3mm (mea-
sured from the bone crest to themost apical point of the
defect) without involvement of furcations, who were
diagnosed clinically, radiographically, and/or intraop-
eratively and were followed for ‡12 months after the
procedure to correct the angular defect.
Compared surgical techniques. The results pub-
lished in the literature concerning the following surgical
techniquesweresearchedandcompared:OFD, includ-
ing open flap curettage, access flap surgery, modified
Widman flap, and papilla preservation flap surgery;
GTR using a bioabsorbable or non-resorbable mem-
brane; regeneration of periodontal tissues using
amelogenin (EMD); and bone or bone substitute
grafts.
Data concerning the techniques were sought
for the following comparisons: OFD versus GTR;
OFDversusEMD;OFDversusboneorbonesub-
stitute grafts; GTRversusEMD;GTRversus bone
or bone substitute grafts; and EMD versus bone
or bone substitute grafts.
Results concerning combinations of the above
treatments (e.g., bone graft beneath a mem-
brane)werenot taken intoconsiderationbecause
the literature available on these techniques is still
scanty and very heterogeneous, and it would be
difficult to determine the contributions of the sin-
gle techniques to the overall results.
Outcomes for professional reference. The
followingvariablesweretakenintoconsideration:
numberof teeth lostover time;variationinclinical
attachment level (CAL gain); variation in PD (PD
gain); variation in gingival recession (Rec); vari-
ation in the bony defect depth (bone gain), from
the bone crest to the most apical point of the de-
fect,measured intraoperativelyorbyx-ray;com-
plications; and adverse reactions.
Outcomes for patients. The following varia-
bles were considered: level of functional satis-
faction and level of esthetic satisfaction.
Other inclusion or exclusion criteria.Only system-
atic reviews of the literature (SRs) of randomized clin-
ical trials (RCTs) and RCTs were selected for these
guidelines. The trial follow-up was ‡12 months. The
reference period included literature published through
December 31, 2006. For statistical analyses, the
RCTs that treatedmore than one site in a single patient
were excluded if they did not take into account the ex-
istence of non-independent sites (patient effect).
Scientific Sources: Identification
An electronic search of the literature through the
end of 2006 was conducted on the following data-
bases: MEDLINE (PubMed), Cochrane Database
of Systematic Reviews, and Cochrane Central Regis-
ter of Controlled Trials (CENTRAL). The electronic
search covered SRs and RCTs. The electronic search
on MEDLINE via PubMed was conducted on April 12,
2007 using the search strategy shown in Table 1.
The electronic search on the Cochrane database
was conducted on April 12, 2007 using the search
strategy shown in Table 2.
In addition to the electronic search, two reviewers
(Drs. Gloria Iachetti and Luisa Guidi, Department of
Periodontology, University of Florence) conducted a
hand search of the literature published from January
1, 2001 to December 31, 2006 in the following jour-
nals: Journal of Periodontology, Journal of Clinical
Table 1.
Search Strategy in MEDLINE (April 12, 2007)
1. Periodontal Pocket/surgery [MeSH] OR Periodontal
Pocket/therapy [MeSH]
2. Alveolar Bone Loss/surgery [MeSH] OR Alveolar Bone
Loss/therapy [MeSH]
3. Intra bony defect* [Tw]
4. Infra bony defect* [Tw]
5. Intrabony defect* [Tw]
6. Infrabony defect* [Tw]
7. OR/1 through 6
8. Open Flap for Debridement [Tw] OR Open Flap Curettage [Tw]
OR Modified Widman Flap [Tw] OR Open Clean-out [Tw]
9. Guided Tissue Regeneration [Tw] OR Guided-Tissue-Regeneration
[Tw] OR Periodontal Regeneration [Tw] OR GTR [Tw]
10. Amelogenin [Tw] OR Emdogain [Tw] OR Enamel Matrix Derivative
[Tw] OR Enamel Matrix Protein [Tw] OR Dental Enamel Protein [Tw]
11. Bone Graft [Tw] OR Autogenous Bone Graft [Tw] OR Allogenic
Bone Graft [Tw]
12. OR/8 through 10
13. 7 AND 12
Limits:
Type of article: meta-analysis and review or RCT
Through December 31, 2006
Humans or animals: humans
MeSH = medical subject heading; Tw = text word.
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Periodontology, Journal of Periodontal Research, In-
ternational Journal of Prosthetic and Restorative Den-
tistry, and Periodontology 2000. Furthermore, SRs
and RCTs were sought in the bibliographies of the se-
lected studies.
The primary objective of the literature search was
to evaluate SRs of RCTs thatmet the inclusion criteria.
If more than one SR was published on the same sub-
ject by the same authors, the most recent SR was se-
lected. The search also sought out any RCTs dated
after the publication of the selected SRs.
In the event that no SR meeting the inclusion crite-
ria was found, the RCTswere evaluated directly. In the
event of more than one RCT conducted on the same
test population, the RCT with the longest follow-up
was considered. The RCTs that treated more than
one site in the same patient were excluded if the sta-
tistical analysis did not take into account the presence
of non-independent sites.
Scientific Sources: Selection
Two independent researchers (MN and UP) analyzed
the complete texts of the selected reviews according
to themethod of the Scottish Intercollegiate Guidelines
Network (SIGN) that calls for the use of checklists pre-
pared specifically for the qualitative evaluation of SRs
with meta-analyses.18
Working independently, five researchers (MN, RR,
and Drs. Gloria Iachetti, Luisa Guidi, and Iana Mervelt,
Department of Periodontology, University of Florence)
analyzed the full texts of the selected RCTs according
to the SIGN method that calls for the use of checklists
for the qualitative evaluation of RCTs.18
At the conclusion of the independent analyses, the
researchers compared their evaluations with the aim
of reaching agreement. If reaching unanimity was dif-
ficult, the final results were obtained after
a discussion involving all members of the
research team.
RESULTS
The electronic search yielded 261 publi-
cations on RCTs via MEDLINE and 194
publications about RCTs in the Cochrane
database. Further, 184 SRs and reviews
of the literature were found on MEDLINE,
and three SRs were located in the Co-
chranedatabase.Thehandsearch starting
from 2001 did not yield any additional ar-
ticles beyond those found with the elec-
tronic search.
Subsequently, reading the abstracts of
all reviews found (184 MEDLINE and
three Cochrane) made it possible to se-
lect nine19-27 that concerned the surgical
techniques under consideration.
At this point, by reading the full texts of the nine se-
lected reviews we accepted the results of two SRs26,27
for the drafting of these guidelines. Seven reviews
were excluded because three19,21,25 were not system-
atic, two22,24 were not SRs of just RCTs, and two20,23
had follow-ups <12 months and did not specify the
depths of the infrabony defects treated.
Of the twoSRs thatwere analyzed, Esposito et al.,26
which permitted comparisons of OFD versus EMD
and EMD versus GTR, was judged to have a very
low risk for bias according to the SIGN checklist
method (SIGN code: 1++). The review by Needleman
et al.,27 which offered a comparison between OFD
and GTR, was also judged to have a very low risk
for bias (SIGN code: 1++).
The search of RCTs published after the reference
period of the two selected SRs and the reading of
the respective abstracts resulted in three RCTs.28-30
They were excluded because two29,30 also reported
data on infrabony defects <3 mm, and the statistical
analysis in the other28 did not take into account the
dependency among the sites in the same patient.
Comparisons of surgical techniques that were
not found through the SRs (bone or bone substitute
grafts versus OFD or GTR or EMD) were searched
by reading the abstracts of all studies found through
the electronic and hand searches of the literature
and bibliographies of the articles. This search identi-
fied 5831-88 RCTs that permitted a comparison be-
tween OFD and bone or bone substitute grafts. A
full reading of the 58 selected RCTs made it possible
to include the results of one83 in the drafting of the
guidelines. Fifty-seven RCTs were excluded; two
RCTs80,81 tested a combination of treatments, three
RCTs82,84,85 dealt with comparisons of other types
Table 2.
Search Strategy in Cochrane Database of
Systematic Reviews and CENTRAL (April 12, 2007)
1. Intra bony [Tw] OR Infra bony [Tw] OR Intrabony [Tw] OR Infrabony [Tw]
2. Open Flap for Debridement [Tw] OR Open Flap Curettage [Tw] OR Modified
Widman Flap [Tw] OR Open Clean-out [Tw]
3. Guided Tissue Regeneration [Tw] OR Guided-Tissue-Regeneration [Tw] OR
Periodontal Regeneration [Tw] OR GTR [Tw]
4. Amelogenin [Tw] OR Emdogain [Tw] OR Enamel Matrix Derivative [Tw] OR
Enamel Matrix Protein [Tw] OR Dental Enamel Protein [Tw]
5. Bone Graft [Tw] OR Autogenous Bone Graft [Tw] OR Allogenic Bone
Graft [Tw]
6. OR/2-5
7. 1 AND 6
Limits:
Reviews and RCTs
Through December 31, 2006
Tw = text word.
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of treatments not covered by these guidelines, one
RCT86 reported data on patients included in previous
studies, five RCTs31,35,38,49,79 were not RCTs (no or
inadequate randomization), two RCTs43,87 reported
data on infrabony defects £3 mm and/or involved fur-
cations, seven RCTs29,45,51,56,60,62,64 treated defects <3
mm, 14 RCTs34,37,44,55,59,61,63,65,68-70,72,74,75 did not
specify themagnitude of the infrabony defects treated,
seven RCTs33,40,50,66,71,76,77 had follow-ups <12
months, and one RCT73 had a variable follow-up rang-
ing from 9 to 13 months. In 14 RCTs,32,36,41,42,
46-48,52,53,57,58,67,78,88 the statistical analysis did not
take into account the dependency among sites in
the same patient, and one RCT54 only reported radio-
graphic data that could not be interpreted (Table 3).
The only RCT included in the evaluation for the
guidelines83 that permitted a comparison between
OFD and grafts of polylactide/polyglycolide (PLA/
PGA) copolymer was judged at high risk for bias ac-
cording to the SIGN checklist (SIGN code: 1-).
In the end, two SRs26,27 made it possible to com-
pare the results for the following techniques: OFD
versus GTR,27 OFD versus EMD,26 and GTR versus
EMD.26 However, the fact that many RCTs that tested
bone or bone substitute grafts did not meet the inclu-
sion criteria for these guidelines (usually because of
the insufficient follow-up or for having treated infra-
bony defects of unstated size or <3 mm) and that just
one RCT83 had a high risk for bias (SIGN code: 1-)
made it impossible to compare OFD versus bone or
bone substitute grafts.
Finally, it was not possible to obtain data that per-
mitted comparisons of GTR versus bone or bone sub-
stitute grafts and EMD versus bone or bone substitute
grafts.
Description of the Studies
In an SR of RCTs55,89-104 with ‡12 months of follow-
up, Needleman et al.27 (Table 4) conducted:
1) A meta-analysis of 16 studies55,89-96,98-104 that
showed a statistically significant CALgain of 1.22mm
(95% confidence interval [CI]: 0.80 to 1.64 mm;
P <0.0001) for GTR versus OFD.
2) A meta-analysis of 11 studies55,93,94,96,98-104
that showed a statistically significant reduction in PD
of 1.21 mm (95% CI: 0.53 to 1.88 mm; P = 0.0004)
for GTR versus OFD.
3)Ameta-analysis of ninestudies55,93,94,98,99,101-104
that showed a statistically significant increase in gingi-
val recession of 0.26 mm (95% CI: 0.08 to 0.43 mm;
P = 0.005) for OFD versus GTR.
4) A meta-analysis of three studies55,89,93 that
showed a statistically significant increase in bone
levels at the second operation (non-resorbable mem-
brane) of 1.39mm (95%CI: 1.08 to 1.71mm) for GTR
over OFD.
A sensitivity analysis conducted by Needleman
et al.27 on only three studies with allocation conceal-
ment and a masked examiner showed a statistically
non-significant advantage in CAL gain of 0.41 mm
(95% CI: -0.33 to 1.08 mm) for GTR over OFD.
In general, healing with GTR and OFD occurred
without any particular complications, other than ex-
posure of the membrane in GTR in 20%90 to 68%94
of the treated sites. The differences in the materials
used, especially between bioabsorbable and non-
resorbable membranes, in the treated sites were
negligible. In any case, this complication frequently
required more appointments for maintenance and
the use of systemic antibiotics.
A multicenter RCT102 that was part of the studies
included in this SR27 reported that there were no sta-
tistically significant differences in the prevalence of
postoperative pain between GTR and OFD; >50% of
the patients did not report this adverse reaction.
Among the patients who experienced pain, the inten-
sity was described with a visual analog scale (VAS)
value of 28.1 – 20 after GTR and 26.4 – 17.6 after
OFD (0 = no pain and 100 = unbearable pain). The
pain lasted for an average of 14.1 – 15.6 hours in
the GTR group and 24.7 – 39 hours in the OFD group
(P = 0.103). Furthermore, 53.6% of the patients in the
GTRgroupand51.8%of the patients in theOFDgroup
reported postoperative discomfort. Of the patients
who underwent GTR and OFD, 35.7% and 32.1%,
respectively, reported that the treatment prevented
them from conducting normal daily activities for
2.7 – 2.3 days (GTR) and 2.4 – 1.3 days (OFD) (P =
0.74). In both groups, the treatment interfered with
work in 25% of the patients. Recreational activities
were hindered in 8.9% of the patients treated with
GTR and in 7.1% of the patients treated with OFD.
Postoperative edema was prevalent in week 1,mainly
among the group of patients treated with GTR (P =
0.01). Hematoma was infrequent during week 1 and
specifically was observed in 7.3% and 5.4% of the pa-
tients treated with GTR and OFD, respectively.
At postoperative week 3, the percentage of sites
with membrane exposure was 53.6%. However, the
difference in clinical attachment gain at the 1-year fol-
low-upbetweenpatientswith exposedandunexposed
membranes was not statistically significant (3.7 –
1.8 mm for the exposed sites and 3.3 – 2.6 mm for
the unexposed sites; P = 0.246).
Finally, Needleman et al.27 did not find data on
teeth lost over time or the patients’ level of functional
and esthetic satisfaction.
Esposito et al.26 (Tables 5 and 6) conducted an SR
of 13 RCTs98,100,103,105-114 with a follow-up ‡12
months with the aim of comparing the use of EMD
toOFD, GTR, and bone or bone substitute grafts. With
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regard to the comparison between EMD and OFD,
they conducted:
1) A meta-analysis of eight studies98,100,103,105,
107,109,111,114 that showed a statistically significant
CAL gain of 1.20 mm (95% CI: 0.71 to 1.69 mm;
P <0.0001) with EMD.
2) A meta-analysis of eight studies98,100,103,105,
107,109,111,114 that showeda statistically significant re-
duction in PD of 0.77 mm (95% CI: 0.54 to 1.00 mm;
P = 0.0001) with EMD.
3) A meta-analysis of five studies98,100,103,107,109
that did not show statistically significant differences
in increased gingival recession for either surgical
technique: 0.04 mm greater for OFD (95% CI: -0.32
to 0.40 mm; P = 0.8).
4) A meta-analysis of two studies105,114 (that re-
ported radiographic measurements of bone level)
which showed a greater, though not statistically signif-
icant, bone gain for the EMD group versus the OFD
group of 1.08mm(95%CI:-0.72 to 2.89mm;P = 0.2).
A further sensitivity analysis extrapolated only two
studies105,114 with a lower risk of bias. In this case, the
differences betweenEMDandOFDwere smaller: CAL
gain with EMD was 0.56 mm greater (95% CI: 0.14 to
0.98 mm) than with OFD, and PD reduction was 0.58
mm greater with EMD versus OFD.
With regard to tooth loss over time, Esposito et al.26
reported that the data were insufficient, and the few
events reported had been caused by prostheses. With
regard to complications and adverse reactions, there
were no particular events in the analyzed trials other
than adverse reactions caused by postoperative
Table 3.
OFD Versus Bone or Bone Substitute
Grafts: Excluded RCTs
Study Reason for Exclusion*
Radhakrishnan and
Anusuya, 200480
Combined treatments
Tonetti et al., 200481
Hanna et al., 200482 Comparisons of
treatments not covered
by these clinical guidelines
Bender et al., 200584
Nevins et al., 200585
Sarment et al., 200686 Patient data included in
previous studies
Ellegaard and Lo¨e, 197131 Not RCT (randomization lacking
or inadequate)Pearson et al., 198135
Sanders et al., 198338
Hiatt et al., 198649
Nevins et al., 200379
Mabry et al., 198543 Data given on infrabony defects
£3 mm and/or on furcationsCamargo et al., 200687
Mellonig, 1984 39 Infrabony defects <3 mm
Renvert et al., 198545
Krejci et al., 198751
Yukna, 199056
Galgut et al., 199260
Borghetti et al., 199362
Mora and Ouhayoun, 199564
Altiere et al., 1979 34 Entity of infrabony defect not
specifiedMovin and Borring-Moller,
198237
Kenney et al., 198544
Blumenthal and Steinberg,
199055
Shahmiri et al., 199259
Meadows et al., 199361
Yukna, 199463
Masters et al., 199665
Zamet et al., 199768
Flemmig et al., 199869
Brown et al., 199870
Froum et al., 199872
Schulz et al., 200074
Rosenberg et al., 200075
Froum et al., 197633 Follow-up <12 months
Chodroff and Ammons,
198440
Louise et al., 198750
Kim et al., 199666
Yukna et al., 199871
Park et al., 200176
Han et al., 200277
Ong et al., 199873 Follow-up ranged from 9 to 13
months
Table 3. (continued)
OFD Versus Bone or Bone Substitute
Grafts: Excluded RCTs
Study Reason for Exclusion*
Carraro et al., 197632 The statistical analysis did not
take the number of
independent sites into account
(patient effect)
Rabalais et al., 198136
Yukna et al., 198441
Meffert et al., 198542
Yukna et al., 198546
Yukna et al., 198647
Schrad and Tussing, 198648
Yukna, 198952
Yukna et al., 198953
Nery et al., 199057
Galgut et al., 199158
Kilic et al., 199767
Mengel et al., 200378
Mengel et al., 200688
Galgut, 199054 Radiographic data could not be
interpreted
* Some studies were excluded for more than one reason.
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antibiotic therapy. There was no difference in post-
operative discomfort (intensity, duration, need for an-
algesics, edema, hematoma, wound healing, and
radicular hypersensitivity), measured with a VAS,
for the two techniques (EMD and OFD) in one
study.113 With regard to patient satisfaction with the
cosmetic results, the investigators reported on only
one trial,113 which did not cite any statistically signif-
icant differences between EMD and OFD (estimate
1.00 [VAS] better for EMD; 95% CI: -5.42 to 7.42;
P = 0.84).
With regard to functional satisfaction,
at the 1-year follow-up in the same
study113 there were high levels of patient
satisfaction with the functional results
(chewing ability, gingival health, ability
to speak, and ease of oral hygiene),
and there were no statistically significant
differences between the two patient
groups (EMDandOFD). The advantages
most frequentlycitedby thepatientswere
the possibility of keeping their teeth and
maintaining or increasing chewing abil-
ity, whereas the costs of the treatments
and the need for many check-ups were
considered the main disadvantages.
In the comparison between EMD and
GTR, Esposito et al.26 conducted:
1) A meta-analysis of five stud-
ies99,100,103,110,112 that showed a statis-
tically non-significant CAL gain of 0.20
mm (95% CI: -0.59 to 0.20 mm; P =
0.3) for GTR versus amelogenin EMD.
2) A meta-analysis of five stud-
ies99,100,103,110,112 that showed a
statistically non-significant reduc-
tion of PD of 0.49 mm (95% CI:
-1.23 to 0.26 mm; P = 0.2) for
GTR versus EMD.
3) A meta-analysis of four stud-
ies99,100,103,112 that showed a sta-
tistically significant increase in
gingival recession that was 0.39
mm greater for GTR (95% CI:
0.13 to 0.66 mm; P = 0.003).
None of the RCTs reported com-
parison data on the teeth lost over
time, variations in bone level, or pa-
tient satisfaction (functional and es-
thetic) for the two techniques.
With regard to complications
and adverse reactions, Esposito
et al.26 reported information from
four studies;98,100,103,110 therewere
no statistically significant differ-
ences in postoperative infections
between EMD and GTR (relative risk, 0.20; 95% CI:
0.01 to 4.09; P = 0.3). There were two cases of ab-
scesses and some membrane exposure in the GTR
group.
Anothermulticenter trial112 reported postoperative
complications without differentiating between minor
(such as flap dehiscence) and major (such as an ab-
scess) events. There were two (6%) complications in
the EMD group and 32 (100%) complications in the
GTR group. The difference was statistically significant
(relative risk, 0.06; 95%CI: 0.02 to 0.24; P = 0.00005).
Table 4.
SR of Needleman et al.27: Results of the GTR Versus
OFD Comparison
Variables Estimate 95% CI P Value Studies (n)
Teeth lost – – – –
CAL gain better
for GTR
1.22 mm* 0.80 to 1.64 mm <0.0001 16
PD reduction better
for GTR
1.21 mm 0.53 to 1.88 mm 0.0004 11
Rec (greater for OFD) -0.26 mm -0.08 to -0.43 mm 0.005 9
Bone gain better
for GTR†
1.39 mm 1.08 to 1.71 mm – 3
Complications Exposed membrane (GTR)
Esthetic satisfaction –
Functional satisfaction –
– = no data.
Characteristics of study: SR of RCT; follow-up ‡12 months; and comparison of GTR versus OFD.
Sign code: 1++.
* 0.41 mm from three RCTs with low risk for bias.
† Data recorded at the second surgical procedure (to remove membrane).
Table 5.
SR of Esposito et al.26: Results of the EMD Versus
OFD Comparison
Variables Estimate 95% CI P Value Studies (n)
Teeth lost – – – –
CAL gain better for EMD 1.20 mm* 0.71 to 1.69 mm <0.0001 8
PD reduction better for EMD 0.77 mm† 0.54 to 1.00 mm 0.0001 8
Rec (greater for OFD) -0.04 mm -0.40 to 0.32 mm 0.80 5
Bone gain better for EMD‡ 1.08 mm -0.72 to 2.89 mm 0.20 2
Complications No difference in postoperative discomfort 1
Esthetic satisfaction better for
EMD
1.00 -5.42 to 7.42 0.84 1
Functional satisfaction –
– = no data.
Characteristics of the study: SR of RCT; follow-up ‡12 months; and comparisons of EMD versus OFD,
GTR, and bone or bone substitute grafts.
Sign code: 1++.
* 0.56 mm from two RCTs with low risk for bias.
† 0.58 mm from two RCTs with low risk for bias.
‡ Data obtained from radiographs.
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Esposito et al.26 did not find any RCTwith details of
the comparison between EMD and bone or bone sub-
stitute grafts.
With regard to the comparison between bone or
bone substitute grafts and OFD, a clinical trial con-
ducted by Minenna et al.83 on 32 patients with infra-
bony defects ‡4 mm made it possible to compare
the clinical results of therapy using PLA/PGA copoly-
mer graft (16 patients with one treated site each) to
OFD (16 patients with one treated site each) after
1 year of follow-up.
Not a single tooth had been lost 12months after the
treatments. Compared to OFD, the PLA/PGA copoly-
mer achieved aCAL gain of 0.2mm (statistically non-
significant), a PD reduction of 0.7 mm (statistically
non-significant), and 0.5 mm greater recession (sta-
tistically non-significant). The investigators did not re-
port data about variations in the magnitude of the
bony defect, complications, or patient satisfaction
levels (functional and esthetic).
GUIDE TO EVIDENCE LEVELS
AND STRENGTH OF THE
RECOMMENDATIONS (TABLE 7)
In accordancewith the suggestions of SIGN,18 the rec-
ommendations in these guidelines distinguish be-
tween those supported by strong evidence and
those based on trials of lower scientific value. It is im-
portant to bear in mind that the grading of a recom-
mendation is not related to the importance of the
recommendation itself, but to the strength of the sup-
porting scientific trials.
The recommendations are classi-
fied by evidence level and strength of
the recommendations in accordance
with the guidelines of the United States
Agency for Health Care Policy and Re-
search,115 amended and introduced in
2000.116
The evidence levels are rated by
four (Arabic) numerals and ++, +,
and - signs (decreasing levels of
evidence: 1++, 1+, 1-, 2++, 2+, 2-, 3,
4). The strength of the recommenda-
tions is classified in four levels
indicated by letters (decreasing
strength levels) from A to D.
The evidence level of a recommen-
dation refers to the probability that
specific knowledge is obtained from
studies with low risk for bias. The
strength of the recommendations re-
fers to the probability that transferring
them to clinical practice can promote
improvement in the health of the pop-
ulation for which the recommendation was made.
RECOMMENDATIONS
Efficacy
Which surgical techniques among OFD, GTR, EMD,
and bone or bone substitute grafts are the best, and
what are the expected clinical results of the treatment
of infrabony defects ‡3 mm in patients who have al-
ready undergone successful causal treatment?
All of the surgical techniques that we compared
(OFD, GTR, and EMD) proved to be capable of
increasing CAL, reducing PD, and promoting an in-
crease in bone at the treated site(s).
There is evidence in the literature that at the 1-year
follow-up, GTR techniques favor greater CAL in-
creases of 1.22 mm (statistically significant), greater
reduction in PD of 1.21 mm (statistically significant),
less increase in gingival recession of 0.26mm (statis-
tically significant), and greater increases in bone
levels of 1.39 mm (statistically significant) with re-
spect to simple access surgery for debridement of
the lesion (OFD)27 (evidence level: 1++; strength of
the recommendation: A).
At the 1-year follow-up, there is evidence in the lit-
erature that EMD can favor a greater increase in CAL
of 1.20mm (statistically significant), a greater reduc-
tion in PD of 0.77 mm (statistically significant), less
increase in gingival recession of 0.04 mm (statisti-
cally non-significant), and a greater increase in bone
level of 1.08 mm (statistically non-significant) com-
pared to simple access surgery for debridement of
the lesion (OFD)26 (evidence level: 1++; strength of
the recommendation: A).
Table 6.
SR of Esposito et al.26: Results of the GTR Versus
EMD Comparison
Variables Estimate 95% CI P Value Studies (n)
Teeth lost – – – –
CAL gain better for GTR 0.20 mm -0.20 to 0.59 mm 0.3 5
PD reduction better for GTR 0.49 mm -0.26 to 1.23 mm 0.2 5
Rec (greater for GTR) 0.39 mm 0.13 to 0.66 mm 0.003 4
Bone gain – – – –
Complications
Postoperative infections
(greater for GTR)
0.20* 0.01 to 4.09 0.3 4
All complications (greater
for GTR)
0.06* 0.02 to 0.24 0.00005 1
Esthetic satisfaction –
Functional satisfaction –
– = no data.
Characteristics of study: SR of RCT; follow-up ‡12 months; and comparisons of EMD versus OFD,
GTR, and bone or bone substitute grafts.
Results of the comparison of EMD versus bone or bone substitute grafts: no RCT found; sign code: 1++.
* Relative risk.
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At the 1-year follow-up, there is evidence in the
literature that GTR techniques are capable of guaran-
teeing results that are essentially comparable to EMD
in terms of CAL increase (0.20 mm for GTR; statisti-
cally non-significant), PD reduction (0.49 mm for
GTR; statistically non-significant), and increased
gingival recession (0.39 mm; statistically signifi-
cant)26 (evidence level: 1++; strength of the recom-
mendation: A).
On the basis of the inclusion criteria for theseguide-
lines and the studies available in the literature, there
are insufficient data for comparing the results of bone
or bone substitute grafts to those obtained with OFD,
GTR, and EMD in the treatment of deep infrabony de-
fects ‡3mm in periodontal patients who have already
undergone successful causal treatment.
Therefore, it is advisable to treat vertical bony de-
fects ‡3 mm with OFD, GTR, or EMD techniques.
GTR and EMD show better results than surgical ac-
cess flaps for debridement in terms ofmeanCAL gain,
mean reduction of PD, and mean bone increment at
the 1-year follow-up (evidence level: 1++; strength of
the recommendation: A).
However, this statement must be viewed with ex-
treme caution because it seems limited by the obser-
vation that when the RCTswith a lower risk for bias are
analyzed, the differences in the treatments decrease,
as in Needleman et al.27 for the comparison between
GTR and OFD, in which the CAL gains in favor of GTR
are reduced and become statistically non-significant
(0.41mm) and in Esposito et al.26 for the comparison
between EMD and OFD, in which the values for CAL
gain and PD reduction in favor of amelogenin EMD
are halved (0.56 and 0.58 mm, respectively). Also,
the studies are often very heterogeneous, and most
of the RCTs had a short follow-up (;12 months).
Furthermore, the choice of one technique over an-
other should take into account the cost/benefit ratio
for the patient from biologic and economic stand-
points; the fact that GTR, EMD, and bone or bone sub-
stitute grafts are usually used to treat one site at a
time, whereas OFD is generally used to treat more
than one site at one time; the anatomic characteristics
of the site to be treated (e.g., number of walls and
depth and angle of the bony defect); the strategic im-
portance of the site to be treated; the professional’s
experience; the ease of performing one technique
over another; and the postoperative comfort of the
patient.
There are insufficient data from randomized studies
to permit an evaluation of all of these factors; there-
fore, such studies should be encouraged.
Complications
What are the possible adverse reactions following
treatment of deep infrabony defects ‡3 mm by
OFD, GTR, EMD, and bone or bone substitute grafts?
In general, only a few trials report these data, and
the available data are scanty. Therefore, the data
available in the literature are insufficient for answering
the question.
In any event, with regard to the comparison be-
tween GTR and OFD, one RCT102 did not report any
significant differences concerning complications
other than postoperative edema, which was more
frequent among patients treated with GTR (P =
0.01) (evidence level: 1+).
For thecomparisonbetweenEMDandOFD,Esposito
et al.26 reported that there were no particular events in
Table 7.
SIGN Grading System18
Levels of Evidence
1++ High-quality meta-analyses, SRs, or RCTs, or RCTs with a
very low risk for bias
1+ Well-conducted meta-analyses, SRs, of RCTs, or RCTs with
a low risk for bias
1- Meta-analyses, SRs of RCTs, or RCTs with a high risk for bias
2++ High-quality SRs of case-control or cohort studies
High-quality case-control or cohort studies with a very
low risk of confounding, bias, or chance and a high
probability that the relationship is causal
2+ Well-conducted case-control or cohort studies with a low
risk for confounding, bias, or chance and a moderate
probability that the relationship is causal
2- Case-control or cohort studies with a high risk of
confounding, bias, or chance and a significant risk that the
relationship is not causal
3 Non-analytic studies, e.g., case report, case series
4 Expert opinion
Grades of Recommendations
A At least one meta-analysis, SR, or RCT rated as 1++ and
directly applicable to the target population; or an SR of
RCTs or a body of evidence consisting principally of
studies rated as 1+, directly applicable to the target
population, and demonstrating overall consistency of
results
B A body of evidence including studies rated as 2++, directly
applicable to the target population, and demonstrating
overall consistency of results; or extrapolated evidence
from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly
applicable to the target population, and demonstrating
overall consistency of results; or extrapolated evidence
from studies rated as 2++
D Evidence level 3 or 4; or extrapolated evidence from studies
rated as 2+
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the trials that they analyzed other than adverse reac-
tions caused by postoperative antibiotic therapy. No
difference in postoperative discomfort between the
two techniques was reported in one RCT113 (evidence
level: 1+).
With regard to the comparison between EMD and
GTR, Esposito et al.26 reported on four stud-
ies.98,100,103,110 There was no statistically significant
difference between EMD and GTR in terms of postop-
erative infections (evidence level: 1++). There were
two cases of abscesses and some membrane expo-
sure in the GTR group, whereas there were no postop-
erative infections or other adverse reactions in the
EMD group.
It is important to mention that the investigators
reported on one multicenter trial112 that described
postoperative complications without differentiating
between minor (e.g., flap dehiscence) and major
(e.g., abscess) ones. There were two (6%) complica-
tions in the EMD group and 32 (100%) complications
in the GTR group. The difference was statistically sig-
nificant (P <0.0001) (evidence level: 1+).
No data were found on other comparisons between
treatment methods; further studies are needed.
Patient Opinions
What is the level of patient satisfaction from functional
and esthetic standpoints with the results ofOFD,GTR,
EMD, and bone or bone substitute grafts after treat-
ment of deep infrabony defects of ‡3 mm?
The data in the literature are insufficient; therefore,
the question cannot be answered.
Only one trial113 reported statistically non-signifi-
cant differences between EMD and OFD in terms of
patient perceptions of functional and esthetic satis-
faction (evidence level: 1+). Further studies on these
aspects should be encouraged and conducted.
SUMMARY OF THE RECOMMENDATIONS
Efficacy
Which surgical technique (OFD, GTR, EMD, or
bone or bone substitute grafts) is most recommend-
able, and what are the predicted clinical results for
the treatment of infrabony defects ‡3 mm in peri-
odontal patients who have already undergone causal
treatment?
Answer: It is advisable to treat vertical bony defects
‡3 mm with OFD, GTR, or EMD (evidence level: 1++;
strength of the recommendation: A). GTR and EMD
can yield better results thanOFD in terms ofCALgain,
reduction of PD, and bone gain after 1 year of fol-
low-up (evidence level: 1++; strength of the recom-
mendation: A). The available data are insufficient
for an evaluation of boneor bone substitute grafts after
1 year.
Complications
What are the possible adverse reactions following
treatment of infrabony defects ‡3 mm with OFD,
GTR, EMD, or bone or bone substitute grafts?
Answer: The data in the literature are insufficient for
answering the question. One study112 reported more
postoperative complications for GTR compared to
EMD (1+). Further studies on these aspects should
be encouraged and conducted.
Patient Opinions
What is the level of patient satisfaction from esthetic
and functional standpoints with the results of OFD,
GTR, EMD, and bone or bone substitute grafts after
treatment of infrabony defects ‡3 mm?
Answer: There are insufficient data in the literature
to answer the question. One study113 suggested that
there are no differences in patient functional and es-
thetic perceptions following treatment with OFD and
EMD (1+). Further studies should be encouraged
and conducted.
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